More and more research i conduct on TauRX I am pretty confident approval will be given either by MHRA or FDA or both within 5- 6 months of providing final data which I assume is sometime this year probably Jan or February which suggests any time between July and September 2024. There are risks of course particularly due to Placebo, issue ..but not all drugs use an placebo. 2nd half results are due in August and run up to this will be very interesting time I reckon.

Couple of positives from PP of shares is that it is cheaper way to fund growth compared to borrowing which reduces profits, and the fact that the shares were not heavily discounted suggests those who prescribed would not have invested if they don’t believe the price will move up and 2.36 should be the floor and we know the profitability will grow rapidly over next 2 -3 years when FPSO come to production and debt is settled…at this point the company may deliver higher dividends in line with of reduction of debt.

Folks at TauRX have the up to date news…I wonder if there is activity within the privately held shares of TauRX which would be the real indicator…if there is no sales means the investors are positive of the outcome and are holding to realise when the company is listed or taken over by big Pharma company.

The problem is epf they effectively control the price so they milk it …that’s why they buy and sell and make a margin from variations in price without actually seeing the price grow….this is pretty much true of the bursa where epf have invested…..that’s is the conclusion I am drawing …we need good spread of investors in particular foreign investment

Good company results , very ambitious highly geared. Problem is people don’t understand it’s business it is generating high profit growth but taking high risks in doing so. Is it managing risks well…yes so far it has…it needs to roll out remaining FPSO quickly and not take on more contracts at the same time. It should begun to maximise its position some in 2027The ceo needs to market the company more to make the shares attractive. As it stands it is not delivering returns to shareholders either in form of price growth or dividends …it can’t give high dividends as it is a growth company with high debts so it has to market its shares…more effectively.

there was a big buy que Friday close. Let’s see what Monday has in store for us before stock goes Xd n 20

Make up your own mind.

https://youtu.be/EALCmZgVibY?feature=shared

https://taurx.com/news-insights/meet-the-taurx-team

Genting Dream Cruise nothing to do with Genting Group or Genting Malaysia! Just in case there is confusion. It emerged bankrupt and rescued.

Big sale triggered after hitting 2.56

Very educational info by OTB. Yinson is no doubt a complex business …with very few capable providers. They essentially provide working capital for their clients.

Yinson has so many buys yet the price is on hold! Manipulation…..big increase before results on the cards.

Consider options or warrants if one is confident about Taurx outcome …possibly with end of year time expiry

Wagering revenue 500,000 USD, this is petty cash ..the big boys who bet on UFC draft Kings have billions in revenue this income is insignificant and volatile ..i some how feel Genting income model is archaic….I think las Vegas resort is good business with good prospects but Catskills is one of the places which has had its time in 1960-70’s….Any way my 2 pennies worth. TauRX however is another ball game if big boss is able and will8mg to allow other shareholders to benefit!

I wonder what target price boss or his close aliens have set to trigger sales…!

Let’s see what holds tomorrow …if stays above 5 than good sign plus 9 sen div ……all counts …next 2 weeks vital as price stabilises and investors will start investing for good news. 1 Qtr will be engineered to be better quarter…..which ends in fortnight ….people already know how of this impairment charge will be out through ..all creative accounting no Impact on cash flow

Hard battle going to keep it above 5! Critical that it remains above. Comparing to Nividia is a 🥹🥹

Still early days …we will have many days when it is up and down….however we all know it is matter of time when Taurx is a reality..even after approval there are many strategic options to consider which is listing of company, tie up with big Pharma etc etc….no impact in terms of revenue ….until much later…but the value of Genting investment in TauRX will be revalued…currently at book cost.

US and Japanese market has been the leaders so far this year. With Japan delivering whopping 43 % return and US 27 % circa return this year, even Europe has been positive. What is worrying is we continue to underperform and when US correction happens which is due, we will follow the correction downwards but never upwards! China and HK is struggling and this needs to reverse, most likely 2025.

The main issue with Taurx is that placebo cannot be used as a comparator. I thought scientifically it can be proven that the drug is effective. Can’t see if additional testing will resolve this issue. The data gathered so far is conclusive…and given its safety profile there is a strong case for approval. Also there is a precedent where approval has been given without a placebo comparator …hopefully the regulators are convinced. On balance there is strong case for approval to be given unless of course politics is in play, which can never be discounted. I feel very positive of the outcome however I impact on Gent price and major shareholder behaviour is the major unknown…still risk / reward ratio is positive

Conference was very positive for TauRX, however I would keep an eye on sell volumes, as there may be people who would initiate a panic sell in order to buy low further good news might be many months later in the year…any drop to 4.50 would be a very good buy…though I would be surprised if it went that low!

I understand that the panel discussion yesterday at the conference post release of test data went very well. This is encouraging. Let’s hope politics don’t impact the approval! With FDA you just don’t know.

OTB…Michael Chan has answered your questions. I am in agreement with him. Just want to add that listing in US is a lengthy process and they are very focussed on governance matters and disclosures so don’t see listing in US soon. Genting Berhad is the better option as it diversified by investing in associates as well as investment in Taurx which we know will be beneficial ultimately.

Sell queues sometimes are not realised the following day. Sell orders are cancelled before market opens….part of the tricks used to ‘cause panic selling. We know that approval for Taurx is matter of time and if one wants to take a chance you have to forget the volatility and focus on the bigger prize.

Today there is a panel discussion and I am sure there will be also some discussion on how to g product to market post approval…. by all accounts all big pharma companies and regulator are presented. The strategy options there to alone and list the company or JV with major Pharma…..listing may be more rewarding but initially more costly.

Like a parrot i f have been repeating. That said I am still invested as at some stage the goal posts will change and the corrupt will all the price to perform.

The poor final results were manufactured for sure through creative accounting …using impairment charges which are very subjective …..we also know that auditors are not independent and have poor record world wide!

We have western professor head of TauRX might as well have the same at Genting! I know there is no chance of that…..We continue with the corrupt souls!

As I said Genting governance is very poor. Last time june 2022 if I remember correctly share price was suspended pending announcement of results which were still effectively in progress until additional 12 month was added to open label. This time the extended test results are even more conclusive and yet no suspension! These things and May Banks timely article needs to be questioned. Foreign investors will keep out due to poor governance. It all stems from owner / CEO …..should be independent western professional CEO …sorry to say that!

JK…yes Taurx, is a private company. The real action and potential will be reflected in share price of TauRX

Genting investors had been bitten too many times and are shy ow when it matters….2024 will be defining year unless boss unloads to invest in mars. I wonder what the price trend is with Taurx share price

Jack Khan fair value before Taurx was 5.70!

Panel discussion today will further cement the outcome and success of the drug. New investors will pile in perhaps foreign flows when market opens later this afternoon. It will take time for news to filter through and ultimate possibilities will run for while. With 1qtr showing uptick things will look better.

Once approval is given or even just before some big pharma company may make an offer to JV or similar to manufacture market and distribute the product. What ever happens 2024 promises to be an exciting year. Remember markets look ahead. Those who sell early may miss out on ultimate gains.

We already know the past results were positive, and were promising, the additional data is being presented can only be positive, otherwise they would not go through this process of expense to present inclusive data! Simple logic…and don’t forget they have already applied for CA ….in my opinion it is already case of When and not of If…..the process to marketing the product and generating revenue is a fairly long one. That said the market is forward looking and investors will begin to make the move early, as suggested by Maybank the strategy could be to invest early or have a good position early …given that Genting is below valuation in May case without Taurx it makes sense to invest at this pricing point. Some folks will trade but the better option is to invest and wait surely,….it is a gamble worth taking ….all stock investment is a gamble.

Actual presentation of test data and results are on 7 March, one should form own opinion on the test data and discussion by the experts to work out probability of CA. Don’t rely on May bank or my other analysts as they are all crooks…playing a double game.

Maybank customers unloading

Reversing already

Still struggling to get over 5 mark! It’s incredible given that even before Taurx potential price should be 5.70 in any case. Suggests there are many investors bought above 5 looking to unload

This could be a false alarm again…but we are getting very close for a positive outcome if not now than later this year.

https://www.businesstoday.com.my/2024/03/05/all-eyes-on-gentings-taurx-alzheimer-phase-3-trial/
We know that approval update is not forthcoming at the conference, however the results of the extended test data will be revealed and discussed at the conference with industry experts. The outcome won which will indicate whether there is a strong probability for CA from the regulatory bodies in UAE, US and U.K. This should be sufficient cause excitement and rerating of Genting share price. Let’s see. Risk / reward on balance is to remain invested or increase investment!

I thought the results will be presented 2nd of the conference.

Get somebody like Tufan E Turkish CEO of Rolls Royce plc aeronautical company, I promise he will sort out Genting in 1 year….he is master of turn around and he is on GBP 1 m plus salary, share options. He is not demand …..the problem is he will find many things thst are being done not to make profit ….!

I honestly think Genting needs a new CEO perhaps from another country and industry….need a professional business manager and not shareholder. Pay should not be an issue as current incumbent earns top tier compared to international markets…in fact he is over paid, fresh blood will invigorate share price

I am sure people in this forum will be happy to learn that IAG (British Airways) made GBP 3b profit increasing by 600% from last year and yet the price fell 3.9% ! Annual profits made up 50% of the value of the business …Shockingly undervalued .We are not alone😀😀. The reason cited, management are very poor in communicating and strategy is also prone to surprises. Sounds very familiar.

Genting P also poor full year results like Sing! What are these guys doing when all other business are recovering Genting is all over over the place. Let’s see tomorrow what holds …

Closing of casinos means more impairment charges,😡in the pipeline.

Good move to close old casinos! Really, why was it not done earlier? Always chasing the game…quite obvious hoards of Chinese tourists have not materialised and further more those that have come are not going to casinos old or new. Makes you wonder how this business is being managed …had so much time during CV19 to review business model and strategy ….! Let’s see …the creating accounting n7menrs when they are presented nobody knows when..not even publised in their web site…these are annual results important ones and here were assuming that will be Thursday/ Friday. So unprofessional when you compare to modern businesses.

Lot of selling but being absorbed so there are buyers…which is encouraging…..sign ! Who is absorbing the sells?